Periodontal Disease Clinical Trial
Official title:
Randomized, Double Blind, Placebo-Controlled, Phase IIB Trial of Ketorolac Mouth Rinse Evaluating the Effect of Cyclooxygenase Inhibition on Oropharyngeal Leukoplakia: Collaborative Study of the NCI, NIDCD and the NIDCR
In Phase II trials, treatment with ketorolac tromethamine oral rinse has been shown to block
periodontal disease progression even in the absence of standard clinical intervention such
as scaling and root planing which is routinely done to reduce the periodontal pathogen load
that is driving the local destructive host inflammatory response. Resolution of periodontal
disease has a favorable effect on normalizing the cellular and biochemical indices of
inflammation as reflected by histological changes as well as the levels of prostaglandin E2
(PGE2) and interleukin I beta (IL-1beta). In this trial, we will prospectively evaluate if
eliminating the inflammatory process (via inhibition of PGE2 biosynthesis) in the oral
cavity has a favorable impact on reversing oropharyngeal leukoplakia. To test this
hypothesis, up to 57 prospectively identified individuals with objective findings of
oropharyngeal leukoplakia will be randomized to receive either a mouth rinse containing
ketorolac or placebo. Ketorolac is a 7-fold selective inhibitor of cyclooxygenase-2 (Cox-2),
which has been designed for local delivery to maximize the drug exposure to critical oral
target tissues while minimizing gastric and systemic exposure to the drug. All responses
will be determined at the three month completion of trial using the response criteria
developed at MD Anderson Cancer Center. The drug will be given for three months and then all
the patients will be followed for one additional month off all oral treatment to observe for
late side effects. Based on the analysis of oral exam and photographically documented change
in the pretreatment area of leukoplakia, the response of all patients will be determined.
The evaluation of the outcome will include a measurable secondary endpoint consisting of an
assessment of histological change as determined by serial punch biopsies of the oral cavity.
In addition, a panel of carcinogenesis and inflammatory markers will be serially measured at
baseline, at one month follow up or at study conclusion. In the residual tissue, other
bioassays will be evaluated to determine their suitability as intermediate endpoint markers.
The purpose of this study is a preliminary evaluation of the effectiveness of ketorolac as a
potential chemoprevention agent for oropharyngeal cancer. If ketorolac administration in
this preliminary Phase IIB trial is associated with reversal of leukoplakia, then a
definitive Phase III chemoprevention trial with a cancer reduction endpoint (most likely in
a cooperative group-type setting) may be the next validation step.
Status | Completed |
Enrollment | 57 |
Est. completion date | June 2004 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
INCLUSION CRITERIA: Patients must have objective evidence of oral leukoplakia. This includes subjects who have had a previous diagnosis of head and neck or oral cancer, who are currently free of evidence of known cancer for at least three months. Patients must have bidimensionally measurable lesions. Patients must consent to serial photography and biopsy to document response to treatment. All patients old enough to give their own informed consent (greater than or equal to 18 years old) are eligible. Subjects must be excellent performance status (Performance Status 0-1). In addition, they must be otherwise medically fit in the opinion of the PI with no other uncontrolled medical conditions. EXCLUSION CRITERIA: Patients with a hypersensitivity to aspirin, lidocaine or non-steroid anti-inflammatory agents or retinoids will be ineligible. Patients using antibiotics, steroids, NSAID, aspirin, probenecid or antihistamines for an extended regimen of at least 10 or more consecutive days, or any immunosuppressants, anticoagulants, dilantin, lithium, methotrexate, phenothiazines, investigational drugs with pharmacological activity that could compromise the test product safety during the 30 days immediately preceding the first treatment visit. Patients with serious or debilitating oral conditions that require extensive dental procedures in order to safely participate in this trial. This trial does not envision the need to do dental procedures (such as root canal or gingival procedure) in order to allow a potential participant to enroll on this study. Individuals with a social or psychiatric situation interfering with study compliance or an unwillingness to undergo the serial oral biopsies will be excluded. Patients with compromised respiratory function manifested by shortness of breath with mild exertion or dependency on supplemental oxygen. Patients with compromised cardiovascular status including poorly controlled angina or congestive heart failure. ELIGIBILITY FOR ORAL IMAGING SUBSTUDY: Participation in this substudy requires that patients be enrolled in the parent trial. Subjects must have given their consent and signed supplemental informed consent for the pilot study involving oral imaging. |
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | National Cancer Institute (NCI) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Cavanaugh PF Jr, Meredith MP, Buchanan W, Doyle MJ, Reddy MS, Jeffcoat MK. Coordinate production of PGE2 and IL-1 beta in the gingival crevicular fluid of adults with periodontitis: its relationship to alveolar bone loss and disruption by twice daily treatment with ketorolac tromethamine oral rinse. J Periodontal Res. 1998 Feb;33(2):75-82. — View Citation
Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science. 1997 Nov 7;278(5340):1073-7. Review. — View Citation
Potter M. Experimental plasmacytomagenesis in mice. Hematol Oncol Clin North Am. 1997 Apr;11(2):323-47. Review. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02618486 -
The Effects of Obesity on Non Surgical Periodontal Therapy
|
N/A | |
Recruiting |
NCT01785355 -
The Impact Of Periodontal Disease Treatment On The General Health Status In Chronic Haemodialyzed Patients
|
||
Completed |
NCT01639183 -
Power Toothbrush Use in Nursing Homes to Eliminate Mouth and Body Inflammation
|
N/A | |
Completed |
NCT02935322 -
Interaction Between Chlorhexidine and Fluoride
|
Phase 4 | |
Completed |
NCT00093236 -
Impact of Gum Infection on Heart Disease
|
N/A | |
Completed |
NCT03444363 -
Periodontal Treatment With Diode Laser in the Patients With Diabetes Melitus
|
N/A | |
Completed |
NCT03641989 -
Correlation Between Oral Health and Systemic Inflammation (COHESION)
|
N/A | |
Withdrawn |
NCT02202304 -
The Effects of Chlorhexidine/Thymol Varnish on Partial Denture Patient
|
Phase 4 | |
Recruiting |
NCT01568697 -
Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
|
||
Completed |
NCT04873505 -
Functional Validation of Lactobacillus Containing Oral Tablet
|
N/A | |
Completed |
NCT01521260 -
Implant Surface Decontamination in Peri-implantitis Treatment
|
N/A | |
Recruiting |
NCT00553007 -
The Relation Between Periodontal Disease and Metabolic Syndrome
|
N/A | |
Completed |
NCT01399034 -
Epigenetics, DNA Methylation Patterns and Periodontal Disease
|
N/A | |
Recruiting |
NCT00162838 -
Effects of Periodontal Pathogens, Porphyromonas Gingivalis and Tannerella Forsythensis, on Cytokine Production From Human Monocyte-Derived Dendritic Cells
|
N/A | |
Completed |
NCT00016835 -
Treating Periodontal Infection: Effects on Glycemic
|
Phase 2 | |
Completed |
NCT03540498 -
Study of Colonization of Strains L.Plantarum and L.Brevis in the Product AB-DENTALAC Chewing Gum
|
N/A | |
Completed |
NCT03775967 -
Estimation of Sialic Acid and IL10 Levels in Stage 1 and 2 Periodontitis Patients
|
||
Completed |
NCT02914743 -
Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes
|
N/A | |
Completed |
NCT02894463 -
Study Aimed at Detecting Potential Abuse of Nitrous Oxide in Children During Dental Care
|
N/A | |
Completed |
NCT02289066 -
Impact of Periodontal Disease on Outcomes in Diabetes
|
N/A |